Biotech Stock News (ATHX) (FLXN)

Athersys (NASDAQ:ATHX) In after-hours trade on February 18, 2016 shares of Athersys were up 21% after the company announced that it had obtained positive phase 2 results for its stroke trial. The phase 2 trial was broken down into two different parts. The first part was a dose selection phase of 16 patients split into … Read more

Biotech Stock News (RPTP) (AERI) (CANF)

Raptor Pharmaceuticals (NASDAQ:RPTP) On Monday September 14, 2015 shares of Raptor Pharmaceuticals ended the day down 38% after the company announced that it had failed a phase 2b liver study in children with NASH — non-alcoholic steatohepatitis. The phase 2b trial enrolled up to 169 children with NASH between the ages of eight and seventeen. … Read more

Biotech Stock News (HZNP)(HPTX)(XON)(SRPT)(MDVN)(ALPMY)(AZN)

Horizon Pharma (NASDAQ:HZNP) Shares of Horizon Pharma ended the day up 18% on March 30, 2015 after the company announced that it would acquire Hyperion Therapeutics (NASDAQ:HPTX) for $955.7 million dollars. Although one thing to note is that this deal for $955.7 million dollars will be a mix of a cash and debt deal. The … Read more

Acadia (ACAD) Stock Tanks | NDA Delay | CEO Retirement

Earlier today, I wrote about the fact that Acadia (ACAD) stock was rising high as investors speculated about a possible takeover by Allergan (AGN). The speculation was the result of delayed investor meetings and investors looking for reasons. However, it seems as though a reason has come to the table. Acadia (ACAD) announced that it … Read more

Biotech News 2/16/15 to 2/20/15

Oncolytics Biotech (ONCY) Shares of Oncolytics gained about 36% on 2/17/15 when it had announced that the company received FDA Orphan Drug Designation status for its pancreatic cancer drug Reolysin. Reolysin is a variant of the ReoVirus which occurs naturally in the environment. Oncolytics has engineered Reolysin to multiply at an alarming rate inside of … Read more

Biotech News- 2/9/15 to 2/13/15

Achillion Pharmaceuticals (ACHN) Shares of Achillion gained 7% on 2/9/15 last week when it had announced that it had achieved a 100% SVR12 in a phase 2 trial treating patients with the genotype 1 version of the Hepatitis C virus — HCV. The trial tested for the primary objective of patients being able to achieve a … Read more